BeiGene, Ltd. (HKG: 6160)
Hong Kong
· Delayed Price · Currency is HKD
138.20
+4.30 (3.21%)
Jan 28, 2025, 12:08 PM HKT
BeiGene Revenue
BeiGene had revenue of 7.35B CNY in the quarter ending September 30, 2024, with 39.54% growth. This brings the company's revenue in the last twelve months to 23.51B, up 50.22% year-over-year. In the year 2023, BeiGene had annual revenue of 2.46B with 73.65% growth.
Revenue (ttm)
23.51B CNY
Revenue Growth
+50.22%
P/S Ratio
n/a
Revenue / Employee
2.22M CNY
Employees
10,600
Market Cap
188.39B HKD
Revenue Chart
* This company reports financials in CNY.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 2.46B | 1.04B | 73.65% |
Dec 31, 2022 | 1.42B | 239.64M | 20.37% |
Dec 31, 2021 | 1.18B | 867.41M | 280.83% |
Dec 31, 2020 | 308.87M | -119.34M | -27.87% |
Dec 31, 2019 | 428.21M | 229.99M | 116.03% |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Dec 31, 2014 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Hansoh Pharmaceutical Group Company | 13.00B |
JD Health International | 58.84B |
WuXi Biologics | 18.39B |
Sinopharm Group | 634.32B |
Alibaba Health Information Technology | 31.39B |
Akeso | 2.01B |
Innovent Biologics | 8.01B |
CSPC Pharmaceutical Group | 33.53B |
BeiGene News
- 15 days ago - BeiGene Stock Meets 80-Plus RS Rating Benchmark - Investor's Business Daily
- 24 days ago - BeiGene Announces Appointment of Giancarlo Benelli as Head of Europe - Business Wire
- 4 weeks ago - BeiGene (BGNE) Stock Rises on FDA Approval for Cancer Treatment - GuruFocus
- 4 weeks ago - BeiGene wins FDA nod for Tevimbra in gastric cancer - Seeking Alpha
- 4 weeks ago - TEVIMBRA Approved in U.S. for First-line Treatment of Gastric and Gastroesophageal Junction Cancers in Combination with Chemotherapy - Business Wire
- 5 weeks ago - BeiGene (BGNE) Announces Ticker Change to ONC Effective January 2025 - GuruFocus
- 5 weeks ago - BeiGene Ltd (BGNE) Announces Ticker Symbol Change to "ONC" in 2025 - GuruFocus
- 5 weeks ago - BeiGene to Change Nasdaq Ticker Symbol to “ONC” on January 2; Present at 43rd Annual J.P. Morgan Healthcare Conference - Business Wire